Huh, G., Lee, H. S., Choi, J. H., Lee, S. H., Paik, W. H., Ryu, J. K., . . . Lee, E. S. (2021). Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: A multicenter, single-arm, open-label, phase 2 trial. SAGE Publishing.
Cita Chicago Style (17a ed.)Huh, Gunn, Hee Seung Lee, Jin Ho Choi, Sang Hyub Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Seungmin Bang, y Eaum Seok Lee. Gemcitabine Plus Nab-paclitaxel as a Second-line Treatment Following FOLFIRINOX Failure in Advanced Pancreatic Cancer: A Multicenter, Single-arm, Open-label, Phase 2 Trial. SAGE Publishing, 2021.
Cita MLA (8a ed.)Huh, Gunn, et al. Gemcitabine Plus Nab-paclitaxel as a Second-line Treatment Following FOLFIRINOX Failure in Advanced Pancreatic Cancer: A Multicenter, Single-arm, Open-label, Phase 2 Trial. SAGE Publishing, 2021.